{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:02:00Z","timestamp":1789682520843,"version":"4.0.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1097\/coc.0b013e3182a0e867","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T21:33:59Z","timestamp":1374701639000},"page":"388-394","source":"Crossref","is-referenced-by-count":30,"title":["Prognostic Significance of Ki67 Expression in Malignant Peritoneal Mesothelioma"],"prefix":"10.1097","volume":"38","author":[{"given":"Krishna","family":"Pillai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Pourgholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence C.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijc.2910310104","article-title":". Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.","volume":"31","author":"Gerdes","year":"1983","journal-title":"Int J Cancer"},{"key":"R2-12-20210128","first-page":"199","article-title":"Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies.","volume":"1","author":"Gerdes","year":"1990","journal-title":"Semin Cancer Biol"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","article-title":". Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.","volume":"133","author":"Gerdes","year":"1984","journal-title":"J Immunol"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown.","volume":"182","author":"Scholzen","year":"2000","journal-title":"J Cell Physiol"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1200\/JCO.2010.31.2835","article-title":". Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.","volume":"29","author":"Cuzick","year":"2011","journal-title":"J Clin Oncol"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-008-0081-7","article-title":". The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.","volume":"116","author":"Jones","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"R8-12-20210128","first-page":"655","article-title":". Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up.","volume":"51","author":"Lazar","year":"2010","journal-title":"Rom J Morphol Embryol"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2407-6-203","article-title":". Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer.","volume":"6","author":"Yang","year":"2006","journal-title":"BMC Cancer"},{"key":"R10-12-20210128","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1046\/j.1365-2559.2003.01613.x","article-title":". Colorectal carcinomas with high MIB-1 labelling indices but low pKi67 mRNA levels correlate with better prognostic outcome.","volume":"42","author":"Duchrow","year":"2003","journal-title":"Histopathology"},{"key":"R11-12-20210128","first-page":"444","article-title":". The proliferation markers Ki-67MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.","volume":"4","author":"Aune","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/ijc.24174","article-title":". Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.","volume":"124","author":"Zellweger","year":"2009","journal-title":"Int J Cancer"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":". Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R14-12-20210128","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":". Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"R15-12-20210128","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1200\/JCO.2008.18.2808","article-title":". Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.","volume":"27","author":"Penault-Llorca","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-12-20210128","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":". Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/000313481007600418","article-title":". Risk factors and clinicopathological study of prognostic factors in the peritoneal mesothelioma.","volume":"76","author":"Tudor","year":"2010","journal-title":"Am Surg"},{"key":"R18-12-20210128","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12253-009-9170-0","article-title":". Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma.","volume":"15","author":"Chua","year":"2009","journal-title":"Pathol Oncol Res"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1477-7819-8-88","article-title":". Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.","volume":"8","author":"Foster","year":"2010","journal-title":"World J Surg Oncol"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1245\/ASO.2006.03.045","article-title":". Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.","volume":"13","author":"Deraco","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R21-12-20210128","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","article-title":". A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database.","volume":"117","author":"Yan","year":"2011","journal-title":"Cancer"},{"key":"R22-12-20210128","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00432-013-1408-2","article-title":"Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.","volume":"139","author":"Pillai","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00795-009-0460-0","article-title":". Malignant mesothelioma of the peritoneum: case reports and immunohistochemical findings including Ki-67 expression.","volume":"43","author":"Hirano","year":"2010","journal-title":"Med Mol Morphol"},{"key":"R24-12-20210128","first-page":"203","article-title":". Immunohistochemical staining of mucin 1 in prostate tissues.","volume":"23","author":"Rabiau","year":"2009","journal-title":"In Vivo"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/1471-2407-11-486","article-title":". Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.","volume":"11","author":"Fasching","year":"2011","journal-title":"BMC Cancer"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.5858\/2006-130-1654-PSOHPI","article-title":". Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma.","volume":"130","author":"Cerruto","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"R27-12-20210128","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2011.04108.x","article-title":". High Wilms tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma.","volume":"60","author":"Scattone","year":"2012","journal-title":"Histopathology"},{"key":"R28-12-20210128","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1158\/1535-7163.MCT-08-0684","article-title":". Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate.","volume":"7","author":"Orth","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1158\/0008-5472.CAN-10-4336","article-title":". Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1091\/mbc.e10-04-0335","article-title":"The proliferation rate paradox in antimitotic chemotherapy.","volume":"23","author":"Mitchison","year":"2012","journal-title":"Mol Biol Cell"},{"key":"R31-12-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/mol.107.039974","article-title":". 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment.","volume":"73","author":"Pattarozzi","year":"2008","journal-title":"Mol Pharmacol"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/13685530701600885","article-title":". Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research.","volume":"10","author":"Gooren","year":"2007","journal-title":"Aging Male"},{"key":"R33-12-20210128","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-08-4523","article-title":". Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.","volume":"69","author":"Pinton","year":"2009","journal-title":"Cancer Res"},{"key":"R34-12-20210128","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/annonc\/mdr477","article-title":". Importance of gender in diffuse malignant peritoneal mesothelioma.","volume":"23","author":"Cao","year":"2012","journal-title":"Ann Oncol"},{"key":"R35-12-20210128","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1183\/09031936.00000811","article-title":". Predicting survival in malignant mesothelioma.","volume":"38","author":"Musk","year":"2011","journal-title":"Eur Respir J"},{"key":"R36-12-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1245\/s10434-006-9169-7","article-title":". Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.","volume":"14","author":"Yan","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R37-12-20210128","first-page":"59","article-title":"Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.","volume":"52","author":"Chua","year":"2009","journal-title":"Can J Surg"},{"key":"R38-12-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","article-title":"Impact of age at diagnosis on prostate cancer treatment and survival.","volume":"29","author":"Bechis","year":"2011","journal-title":"J Clin Oncol"},{"key":"R39-12-20210128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1015764507609","article-title":"Effect of young age on prostate cancer survival: a population-based assessment (United States).","volume":"13","author":"Merrill","year":"2002","journal-title":"Cancer Causes Control"},{"key":"R40-12-20210128","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(09)70028-2","article-title":". Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England.","volume":"10","author":"Rachet","year":"2009","journal-title":"Lancet Oncol"},{"key":"R41-12-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.critrevonc.2008.03.005","article-title":". The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region.","volume":"67","author":"van Leeuwen","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"R43-12-20210128","doi-asserted-by":"crossref","first-page":"9234","DOI":"10.1158\/0008-5472.CAN-10-1190","article-title":". Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer.","volume":"70","author":"Rahmanzadeh","year":"2010","journal-title":"Cancer Res"},{"key":"R44-12-20210128","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1021\/cr0306743","article-title":"Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy.","volume":"107","author":"Famulok","year":"2007","journal-title":"Chem Rev"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e3182a0e867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T11:59:17Z","timestamp":1688385557000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201508000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3182a0e867","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}